Moreover, the prostate cancer cells used in this study do not express detectable levels of the PR and as such, any ARCC-4 induced signaling or proliferation effects can be solely attributed to AR degradation and not PR-A or PR-B suppression. This evidence concerns the gene S100A6 and prostate cancer.